Inspirna
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Inspirna was a New York City-based cancer biotech company, originally founded as RGENIX from science at Rockefeller University and renamed Inspirna in 2021. It developed first-in-class drugs targeting key pathways in cancer progression using a microRNA-based target discovery platform called RNA-DRIVEr, which identified novel therapeutic targets in the tumor microenvironment. Its lead therapy, RGX-104, was a small-molecule immunotherapy blocking tumor immune evasion that obtained FDA Orphan Drug Designation in several solid tumor types and entered clinical trials in late 2016. The company raised more than $140 million from investors including Novo Holdings, Sofinnova Partners, Exor and Vivo Capital, and wound down in March 2025.
02 / Inspirna FAILURE REASONS
Failure reasons
CEO Usman Azam announced the wind-down on LinkedIn on March 31, 2025, saying the company was closing completely after ten years, but gave no official reason for the decision and no details on staff numbers. The company's last financing was a $50 million Series D in July 2022, roughly three years before the closure; no pipeline or financial catalyst was disclosed, and no postmortem has been published. The closure fits a broader 2025 trend of private biotechs shutting down, but nothing specific to Inspirna's reasons is on the record.
03 / EVENT HISTORY
Events in the structured record
- Operations ended
reporting CEO Oz Azam LinkedIn statement (31 Mar 2025) that Inspirna is winding down after 10 years; article states the oncology company is closing completely. ClinicalTrials.gov NCT05983367 (Inspirna Phase 2 ompenaclid) listed TERMINATED same day with 'results did not meet the primary endpoint'.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Inspirna raised more than $140 million over several investment rounds from Novo Holdings, Sofinnova Partners, Exor, K2 HealthVentures and Vivo Capital, including a $50 million Series D in July 2022.
- 02
On March 31, 2025 the company announced it was winding down completely; no asset-sale, creditor-settlement or IP-transfer terms were disclosed.